US2022184043A1PendingUtilityA1

Methods of treating inflammatory bowel disease with amd3100 and tacrolimus

75
Assignee: MEDREGEN LLCPriority: Dec 11, 2009Filed: Mar 2, 2022Published: Jun 16, 2022
Est. expiryDec 11, 2029(~3.4 yrs left)· nominal 20-yr term from priority
Inventors:Zhaoli SunXuhang Li
A61K 31/506A61P 13/12A61K 38/13A61K 45/06A61K 31/436A61K 31/395A61K 9/08A61P 9/10A61K 31/4427A61K 31/00A61K 38/19A61K 9/4841A61K 31/365A61P 37/06A61K 9/0019A61K 38/193A61P 17/00A61K 38/18A61K 9/10A61P 1/16A61K 9/0095A61K 9/107A61K 9/2004
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A dosing regimen comprising:
 administering to a patient with inflammatory bowel disease a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent.   
     
     
         2 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is selected from the group consisting of AMD3100, AMD3465, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         3 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is a CXCR4 antagonist. 
     
     
         4 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is AMD3100. 
     
     
         5 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is selected from the group consisting of Tacrolimus, cyclosporine, Orthoclone OKT3, mycophenolate and sirolimus. 
     
     
         6 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is Tacrolimus. 
     
     
         7 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is administered in a low dose amount. 
     
     
         8 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is AMD3100 and the immunosuppressive agent is Tacrolimue. 
     
     
         9 . A dosing regimen comprising:
 administering to a patient with inflammatory bowel disease a therapeutically effective amount of an agent that mobilizes at least one of CD34 +  and CD133 +  stem cells and a low dose of an immunosuppressive agent.   
     
     
         10 . The dosing regimen of  claim 9 , wherein the agent that mobilizes at least one of CD34 +  and CD133 +  stem cells is AMD3100 and the immunosuppressive agent is Tacrolimus.

Join the waitlist — get patent alerts

Track US2022184043A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.